Advances In Biology And Therapy Of Multiple Myeloma

Advances In Biology And Therapy Of Multiple Myeloma

About
Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients.   This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.

Discuss Advances In Biology And Therapy Of Multiple Myeloma with other readers

Join or start a book club for Advances In Biology And Therapy Of Multiple Myeloma on Readfeed. Live chat, shared reading progress, and AI discussion questions — free to get started.

Frequently asked questions

How do I join a book club for Advances In Biology And Therapy Of Multiple Myeloma?

Sign up free on Readfeed, then browse public clubs or start your own club with Advances In Biology And Therapy Of Multiple Myeloma as the current read. Invite friends with a share link and discuss together with live chat and AI discussion questions.

Can I discuss Advances In Biology And Therapy Of Multiple Myeloma with other readers online?

Yes. Readfeed book clubs let you chat live, share progress, and join discussions about Advances In Biology And Therapy Of Multiple Myeloma with readers worldwide — whether your club is virtual, in-person, or hybrid.

Is Readfeed free?

Yes. Creating an account and joining book clubs is free. Sign up to find readers who love the same books and start discussing today.